慢性乙型和丙型肝炎对肝硬化和肝癌风险的影响超过MASLD
该前瞻性队列研究纳入336,866名≥30岁健康筛查成人,随访至2019年,评估MASLD与慢性乙肝或丙肝感染对抗病毒治疗状态下肝硬化和肝细胞癌(HCC)风险的影响。结果显示,慢性乙肝或丙肝感染相关HCC风险(HRadj 8.81和8.86)远高于单纯MASLD(HRadj 1.52),且在抗病毒治疗患者中MASLD仍增加肝硬化和HCC风险。结论强调应优先治疗慢性病毒性肝炎再处理MASLD。
要点
- 慢性乙肝或丙肝感染者的HCC风险约为无感染无MASLD者的8.8倍,远超单纯MASLD的1.5倍。
- 在接受抗病毒治疗的慢性乙肝或丙肝患者中,合并MASLD仍与肝硬化和HCC风险升高相关。
- 临床应优先治疗慢性病毒性肝炎,再处理MASLD。
核心结论
- 慢性乙型或丙型肝炎感染对肝硬化和HCC的风险影响大于MASLD,应优先治疗慢性病毒性肝炎。
研究设计与样本
- 前瞻性队列研究,1997-2013年纳入336,866名≥30岁健康筛查成人,随访至2019年12月31日。
- MASLD通过腹部超声和心血管代谢指标定义,数据链接全国医保、癌症登记和死亡认证系统获取抗病毒治疗、生命状态及新发肝硬化与HCC信息。
主要发现
- 总人群122,669人(36.4%)有MASLD;平均随访15年,新发肝硬化5,562例、HCC 2,273例。
- MASLD显著增加肝硬化和HCC累积风险(P < .0001),但慢性乙肝或丙肝感染的相关风险更为显著。
- 以无MASLD且无慢性乙肝或丙肝为参照,HCC的HRadj(95%CI)为:无MASLD伴慢性乙肝或丙肝8.81(7.83-9.92),单纯MASLD 1.52(1.32-1.74),MASLD伴慢性乙肝或丙肝8.86(7.76-10.12),均P < .0001。
- 在随访期间接受抗病毒治疗的慢性乙肝或丙肝患者中,MASLD与肝硬化风险升高相关(HRadj 1.23,95%CI 1.01-1.49),与HCC风险升高相关(HRadj 1.32,95%CI 1.05-1.65)。
临床怎么用
- 对慢性乙肝或丙肝感染者应优先启动抗病毒治疗,再评估和管理MASLD。
- 接受抗病毒治疗的慢性乙肝或丙肝患者合并MASLD时,仍需关注肝硬化和HCC风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on the development of cirrhosis and hepatocellular carcinoma (HCC) by chronic hepatitis B (CHB) or C infection and antiviral treatment statuses is not well-known. METHODS: A total of 336,866 adults aged ≥30 years were prospectively enrolled in a health screening program between 1997-2013. MASLD was identified by abdominal ultrasonography and cardiometabolic profiles. Data linkage was performed using 3 nationwide databases-National Health Insurance, Cancer Registry, and Death Certification System-to obtain information on antiviral treatment, vital status, and newly diagnosed cirrhosis and HCC. Follow-up was conducted until December 31, 2019. RESULTS: In the total population, 122,669 (36.4%) had MASLD. Over a mean follow-up of 15 years, 5562 new cases of cirrhosis and 2273 new cases of HCC were diagnosed. Although MASLD significantly increased the cumulative risks of cirrhosis or HCC (P < .0001), the associated risk was more pronounced when comparing CHB or C infection with the presence of MASLD. Stratifying the participants based on their MASLD and CHB or C statuses, hazard ratios (HRadj) with 95% confidence intervals for HCC were 8.81 (7.83-9.92) for non-steatotic liver disease (SLD) with CHB or C, 1.52 (1.32-1.74) for MASLD without CHB or C, and 8.86 (7.76-10.12) for MASLD with CHB or C, compared with non-SLD without CHB or C (all P < .0001). Among CHB or C patients who received antivirals during follow-up, MASLD was associated with increased risks of cirrhosis and HCC, with HRadj of 1.23 (1.01-1.49) and 1.32 (1.05-1.65), respectively. CONCLUSIONS: These findings underscore the need to prioritize treatment of chronic viral hepatitis before addressing MASLD.
引用
- Lee MH, Chen YT, Huang YH, et al. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC. Clin Gastroenterol Hepatol. 2024. PMID: 38365094. doi:10.1016/j.cgh.2024.01.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。